Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-08-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: surgeryhours000failurecatheter
  Phrases that lowered it: clinically relevantthe efficacyproductsthe studydoses
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.3% (raises risk) · Sponsor's track record
• Collaborators: 7 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 118 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Drug's FAERS reports with a death: 18.4% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 17 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 34418 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 91.2% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 486 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer NCT00633061 · started 2008 · scored riskier than 98% of active trials terminated
• Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients NCT01343680 · started 2011 · scored riskier than 32% of active trials terminated
• Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines NCT03506815 · started 2019 · scored riskier than 54% of active trials completed
• A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) NCT06299111 · started 2024 · scored riskier than 78% of active trials completed
• Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI) NCT01539343 · started 2013 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.